JPMorgan Resumes Pfizer (PFE) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Jefferies Reiterates Buy on Pfizer (PFE) Post Allergen Collapse, PT Trimmed to $39
April 7, 2016 8:23 AM EDTJefferies analyst, Jeffrey Holford, performed a SOTP valuation on fizer (NYSE: PFE) after the Allergan deal was terminated and believes shares have 18% upside by 2017 as the decision on the split has been reinstated to 2016. He also sees the potential for major M&A to give more critical mass to GIP in particular. Using a SOTP analysis, he derives a value of... More
Pfizer (PFE) Announces Termination of Merger Agreement with Allergan (AGN)
April 6, 2016 6:45 AM EDTPfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change... More
